

Omacetaxine as an Anticancer Therapeutic: What is Old is New Again

Meir Wetzler* and David Segal

Metabolic Research Unit, School of Medicine, Faculty of Health Medicine Nursing & Behavioural Sciences Deakin University Geelong 3217, Australia

Abstract: Omacetaxine mepesuccinate was originally identified more than 35 years ago and initial studies in chronic myeloid leukemia (CML) showed promising activity. It has also been studied in other hematologic and solid tumors as both a single agent and in combination with other treatments. However, the introduction of imatinib and related tyrosine kinase inhibitors (TKIs) abated the clinical development of omacetaxine as a treatment for CML. The advent of resistance to imatinib and other TKIs in CML patients (often due to the presence of an ABL mutation at position 315) has led to a revived clinical interest in omacetaxine in CML patients who failed TKIs. Here we review omacetaxine's mechanism of action (MOA) as a protein translation inhibitor, how its MOA may translate into activity in treatment of cancers, its potential to eradicate leukemia initiating cells and other cancer stem cells and the potential significance of this activity in clinical practice.

Keywords: Omacetaxine, protein translation inhibition, chronic myeloid leukemia, leukemia initiating cells, cancer stem cells.

INTRODUCTION

Omacetaxine mepesuccinate (formerly known as homoharringtonine) was originally identified over 35 years ago as a novel plant alkaloid with antitumor properties. The use of omacetaxine as an anticancer therapeutic has been explored in a wide range of solid and hematological malignancies; however, omacetaxine has not yet been approved for clinical use by the United States Food and Drug Administration. The purpose of this review is to discuss omacetaxine's unique mechanism of action (MOA) and how it might be exploited to treat a variety of cancers.

OMACETAXINE AS A PROTEIN TRANSLATION INHIBITOR

Omacetaxine was found to be an inhibitor of protein translation early on in the investigation of its MOA. Using purified ribosomes and synthetic mRNAs these initial studies showed that omacetaxine inhibits protein translation by preventing the initial elongation step of protein synthesis via an interaction with the ribosomal A-site [1, 2]. The MOA of omacetaxine differs from other translation elongation inhibitors in that omacetaxine acts only on the initial step of protein translation and does not inhibit protein synthesis from mRNAs that have already commenced translation. This is in contrast to other peptidyl transferase center inhibitors such as cycloheximide and anisomycin that inhibit peptide formation on mRNAs that are actively translated. Recent crystallographic studies have provided a clear structural basis for the inhibition of protein synthesis by omacetaxine [3]. By binding the A-site cleft in the peptidyl-transferase center of the ribosome, omacetaxine inhibits protein synthesis by preventing the correct positioning of amino acid side chains of incoming aminoacyl-tRNAs.

In the past, inhibition of protein translation has been thought to be too general an effect and offer little in the way of selectively targeting cancer cells. As the understanding of the regulation of protein translation has grown however, it has become clear that protein translation is markedly up-regulated in cancer cells and high levels of short-lived proteins involved in cell division and survival are required in many cancer types [4]. Interest in the development of novel protein translation inhibitors has dramatically increased recently. This interest is highlighted by the number of novel compounds targeting various aspects of protein translation in clinical

trials in a range of different cancer types [5]. Examples of a number of protein translation inhibitors and their MOA are illustrated in Fig. (1).

Protein translation inhibitors are diverse in their MOA and they exhibit different effects on different mRNAs and the proteins they encode. For example, inhibitors of protein translation initiation (such as silvestrol [6]) preferentially inhibit the translation of mRNAs with 5'UTRs that are G/C rich and complex 3-dimensional structures. Some of the proteins encoded by these mRNAs are important factors in cancer cell proliferation and survival (e.g., c-Myc, Mcl-1 and Cyclin D1) and the selective loss of these proteins is thought to be part of the MOA of inhibitors of protein translation initiation. In contrast to inhibitors of protein translation initiation, omacetaxine leads to a general decrease in translation efficiency of all mRNAs independent of the template they encode [7]. Despite this general activity, the short-term effect of omacetaxine on cells is the rapid loss of proteins with short half-lives [7-10]. Interestingly, a number of proteins with short half-lives are encoded by the same cell survival and proliferation mRNAs that possess complex 5'UTRs described above (e.g., c-Myc, Mcl-1 and Cyclin D1) and the loss of these proteins appear to be integral to omacetaxine's MOA.

One of the key effects of omacetaxine is the rapid loss of c-Myc protein and the consequent down-regulation of c-Myc responsive genes. Of particular note in the context of the current discussion, is the transcriptional regulation of protein translation machinery by c-Myc as c-Myc is part of a feed forward loop whereby increased expression of c-Myc protein promotes expression of elongation initiation factor 4F (eIF-4F) proteins and promotes translation of mRNAs that possess complex 5'UTRs (which includes c-Myc). This feed forward loop is thought to be part of the mechanism by which c-Myc up-regulation leads to tumorigenesis [11, 12]. As c-Myc is preferentially lost from cells treated with omacetaxine, levels of mRNAs encoding eIF-4F proteins are likely to be rapidly reduced (i.e. <4 hours) and augment the direct effects of omacetaxine via this indirect down-regulation of protein translation initiation.

OMACETAXINE IN CHRONIC MYELOID LEUKEMIA AND OTHER CANCERS

Protein translation in Bcr-Abl positive cells is up-regulated via Bcr-Abl mediated activation of phosphoinositide-3-kinase (PI3K)/AKT/mammalian target of rapamycin (mTOR) signaling pathways. Activation of mTOR in Bcr-Abl positive cells leads to phosphoryla-

*Address correspondence to this author at the Leukemia Section, Department of Medicine, Roswell Park Cancer Institute, Elm and Carlton Streets, Buffalo NY 14263, USA; E-mail: meir.wetzler@roswellpark.org




Fig. (1). Mechanism of action of current and future protein translation inhibitors. Abbreviations, 4E-BP1, 4E binding protein 1; EIF, eukaryotic translation initiation factor; mTOR, mammalian target of rapamycin; P, phosphorylated; p70S6K, ribosomal protein S6, 70kDa, polypeptide 2.

tion of S6 kinase and 4E-binding protein (4E-BP), key steps in translation of mRNAs with complex 5'UTRs [13, 14]. *In vitro* experiments have shown that inhibition of Bcr-Abl by the tyrosine kinase inhibitor (TKI) imatinib markedly reduced protein translation initiation. In light of these findings it is perhaps not surprising that imatinib has been found to interact synergistically in causing apoptosis of Bcr-Abl positive cells treated with compounds that interfere with translation directly or regulate protein translation initiation. The agents include omacetaxine [8], the mTOR inhibitor rapamycin [15] and the mitogen activated protein kinase interacting serine/threonine kinase 1 (MNK1)/p90 ribosomal S6 kinase (p90RSK) inhibitor CGP-57380 [16]. Omacetaxine has also been found to reduce Bcr-Abl protein levels in Bcr-Abl positive cells [8, 17]. These studies raise the possibility that the efficacy of current chronic myeloid leukemia (CML) therapy with TKIs may be increased by combination treatment with omacetaxine.

Omacetaxine has been found to induce the rapid loss (<4 hours) of a number of short-lived proteins from a number of cell lines derived from CML, acute myeloid leukemia (AML), chronic lymphocytic leukemia (CLL) and multiple myeloma patients [9, 10, 18]. These include Mcl-1, Cyclin D1, c-Myc, X-linked inhibitor of apoptosis (XIAP), β -Catenin and the long isoform of cellular FLICE [FAS-associated death-domain-like interleukin (IL)-1 β -converting enzyme] inhibitory protein (c-FLIP_L). For example, Mcl-1 is up regulated in all AML classes and mouse genetic models clearly indicate that loss of Mcl-1 is protective against AML [19]. Moreover, clinical data suggest that omacetaxine kills AML cells *in vitro* and this is associated with a loss of Mcl-1 and Phase II clinical

trial data suggest that omacetaxine may have clinical benefit in AML patients [20-24]. Similar effect of omacetaxine on Mcl-1 was recently described in CLL [25]. Lastly, omacetaxine was shown to decrease the level of Kit protein by inhibiting its translation, leading to a decreased level of the phosphorylated native and mutated proteins [26]. These results suggest a role for omacetaxine in mastocytosis. These short-lived proteins clearly regulate proliferation and cell survival and their loss is likely to be involved in the apoptosis induced by omacetaxine in cells that absolutely require the expression of one or all of these proteins for survival.

The loss of proliferation and cell survival proteins induced by omacetaxine may, however, not be sufficient to induce apoptosis in many cancer types due to the presence of a number of dysregulated survival pathways. The loss of these short-lived proteins may however sensitize cancer cells to the action of other anti-cancer therapeutics. This possibility is highlighted by a recent study by Robert *et al.* [7] showing that combination therapy of omacetaxine and the DNA damaging agent doxorubicin were highly effective in prolonging survival in murine E μ -myc lymphoma models whilst either agent alone were largely ineffectual. In addition, rational combination therapies may be used to take advantage of the decrease in anti-apoptosis short-lived proteins induced by omacetaxine. For example, cells that express high levels of the anti-apoptotic Bcl-2 family proteins Bcl-2, Bcl-x_L and Mcl-1 are resistant to the Bcl-2/Bcl-x_L inhibitor ABT-737 due to the inactivity of ABT-737 on Mcl-1. Combination therapy of omacetaxine and ABT-737 showed a marked synergistic interaction in CML and multiple myeloma cells due to the reduction of Mcl-1 protein by omacetaxine and inhibition

of Bcl-2 and Bcl-x_L activity by ABT-737 [11, 18]. It is also notable that agents that inhibit transcription (such as flavopiridol and SNS-032) exhibit marked synergistic interaction with omacetaxine in CML and CLL cells [8]. As all three of these compounds lead to a loss of short-lived proteins, this approach may offer mechanistic synergism and may therefore help reduce the frequency of acquired resistance during therapy of patients with these conditions.

Pro-apoptotic signaling by tumor necrosis factor (TNF)-superfamily proteins is inhibited in part by negative regulators such as c-FLIP_L and XIAP. As described above, these short-lived proteins are rapidly lost from cells treated with omacetaxine [9]. As a result, it is tempting to hypothesize that omacetaxine will sensitize cells to the effects of TNF-superfamily proteins such as TNF-related apoptosis-inducing ligand (TRAIL) and TNF- α . This possibility is supported by recent data showing that omacetaxine interacted synergistically with an adenovirus that overexpresses human TRAIL in causing apoptosis of myeloid leukemia cells [27]. In addition, c-FLIP_L is a key negative regulator of spontaneous TNF receptor superfamily activation in cells undergoing cell death (or anoikis) following detachment from the extracellular matrix. Omacetaxine and the translation elongation inhibitor anisomycin were found to preferentially sensitize resistant prostate cancer cells (PPC-1) to anoikis [28]. These findings suggest that omacetaxine may be useful in selectively killing cells that are anchorage independent and have high metastatic potential.

OMACETAXINE AND LEUKEMIA INITIATING CELLS

Leukemia initiating cells (LICs) are a population of stem cells that are capable of tumor initiation and maintenance of the disease. LICs, in CML, are thought to reside in a population of Bcr-Abl positive cells with characteristics of hematopoietic stem cells. A number of studies have shown that current TKIs do not kill these cells at high frequency but rather cause apoptosis in more differentiated Bcr-Abl positive cells of myeloid and lymphoid lineage (reviewed by Jorgensen, *et al* [29]). As a result, we do not know whether TKIs have the potential to cure CML patients of their disease and the patients relapse in the majority of cases following therapy cessation [30]. Recently, omacetaxine, but not the TKI imatinib, was found to induce apoptosis in Bcr-Abl positive LICs in a mouse model of CML [17]. In addition, experiments using primitive CD34⁺CD38⁻ LICs from CML patients showed that omacetaxine can effectively kill Bcr-Abl positive LICs *in vitro* [31]. These data indicate that omacetaxine induces its effects at least in part by targeting the CML LIC population. This raises the possibility that omacetaxine alone or in combination a TKI (such as imatinib, nilotinib or dasatinib) or cytokines (such as interferon- α) that activate the proliferation of CML LICs and increase their sensitivity to cytotoxic compounds may be used to eliminate these CML LICs.

The reason why omacetaxine targets Bcr-Abl positive LICs, while TKIs do not, is unclear at present. It may be that Bcr-Abl positive LICs require expression of certain short-lived proteins and these are preferentially lost following treatment with omacetaxine but not TKIs. Recent data have shown that omacetaxine induces the rapid (<4hr) loss of the anti-apoptotic protein Mcl-1 from Bcr-Abl positive LICs [31] and this may be sufficient to induce apoptosis in these cells. The loss of another short-lived protein, β -Catenin [a key mediator of wntless-type MMTV integration site family protein (Wnt) signaling], impairs the renewal of Bcr-Abl positive CML LICs and reduces the ability of Bcr-Abl to cause leukemia in CML mouse models [32, 33]. Interestingly, recent screening data from the Broad Institute [34] have found that omacetaxine preferentially kills cells that are dependent upon Wnt signaling. As omacetaxine has been shown to cause the rapid loss of β -Catenin in myeloma cell lines [9], it is tempting to speculate that omacetaxine may cause the loss of Bcr-Abl positive LICs by deleting β -Catenin from this cell population.

Another proposed mechanism of CML LICs' resistance to TKIs is cytokine-dependent activation of anti-apoptotic and pro-mitogenic signaling cascades. The cytokine, IL-3, is responsible for cell survival in CML LICs. A very recent study by Klag *et al* [35] indicates that omacetaxine can induce down-regulation of the beta-subunit of the IL3-receptor in primary stem cell cultures at clinically relevant concentrations (40nM) of omacetaxine, eliminating or reducing the binding sites for IL-3.

OMACETAXINE AND CANCER STEM CELLS

Cancer stem cells (CSCs) are a population of cells that, similar to LICs described above, are capable of tumor initiation and maintenance of the disease (reviewed in [36]). Epithelial CSCs are relatively rare and exhibit resistance to chemotherapeutic agents compared with other cancer cells. This resistance of CSCs to conventional therapies is thought to be one mechanism by which cancer therapies fail to clear the tumor completely leading to recurrence of the tumor and disease progression. Of note is that epithelial CSCs have mesenchymal characteristics with respect to morphology and expression of cell surface markers. In a recent screen for compounds that specifically target CSCs, Gupta *et al.* [37] found that knockdown of E-cadherin (a marker of epithelial cells) in epithelial HMLER breast cancer cells induced epithelial-mesenchymal transition and an increase in treatment resistant CSCs. In a screen based on this cell line, a number of compounds (such as salinomycin) were found to specifically induce apoptosis in CSCs. These compounds represent a novel therapeutic strategy that may be used to specifically target CSCs and thereby improve therapeutic outcomes. As part of this screening effort omacetaxine was found to selectively kill CSCs [34]. These findings suggest that omacetaxine may be used in combination with other front-line therapies to preferentially deplete CSCs and improve the duration of remission induced by current therapeutic interventions in epithelial cancers such as breast, ovarian and lung cancers.

OMACETAXINE CLINICAL DEVELOPMENT IN CML AND OTHER HEMATOLOGIC MALIGNANCIES

CML is characterized by the clonal expansion of a hematopoietic stem cell possessing a reciprocal translocation between chromosomes 9 and 22. This translocation results in the head-to-tail fusion of the *BCR* gene on chromosome 22q11 with the *ABL* gene located on chromosome 9q34. Attachment of *BCR* sequences to *ABL* converts Abl to a constitutively active tyrosine kinase. Untreated, the disease is characterized by the inevitable transition from a chronic phase to an accelerated phase and on to blast crisis in a median of four years. CML treatment revolutionized following the introduction of the TKI, imatinib; 95% of patients achieve hematologic remission and 76% achieve complete cytogenetic remission at 18 months. Further, all imatinib-treated patients who achieved major molecular remission, defined as ≥ 3 log reduction in *BCR/ABL* transcript level at 18 months were progression-free at five years. However, approximately 15% of patients discontinue imatinib treatment due to unsatisfactory outcome, resistance being the most common cause. The most frequent reason (40%-50%) for treatment failure is development of mutations in the Abl kinase domain of Bcr-Abl. Of these mutations, a conversion of the amino acid threonine to isoleucine at position 315 (T315I) is resistant to all currently developed TKIs. These patients are in need of other treatments [38].

Before the development of imatinib, the main treatment for CML patients was interferon α that led to reduction in disease burden and a modest survival benefit compared with other treatments. The limited efficacy of interferon α and a high frequency of intolerable toxicities led to the search and discovery of omacetaxine, an alkaloid derivative from the Chinese yew tree [39]. In initial studies, omacetaxine, as a single agent, was found to induce cytogenetic remission in 31% of interferon- α resistant patients [40] and com-

binning it with interferon α induced cytogenetic responses in 25% of newly diagnosed CML patients [41].

In initial Phase I and II clinical studies, omacetaxine was administered intravenously using short (<6 hour) and continuous infusion schedules. In these initial studies, short term administration was associated with unacceptable cardiac toxicity however multi day (>7 days) continuous infusion regimens were found to be better tolerated and induce greater therapeutic benefit (reviewed in [42]). In more recent clinical trials, omacetaxine was administered subcutaneously twice daily for 14 days with similar efficacy and toxicity profiles as with continuous infusion [43, 44]. Pharmacokinetic studies show that omacetaxine undergoes rapid hydrolysis of the methyl ester in plasma to an inactive metabolite [45] and omacetaxine delivered by either subcutaneous or continuous infusion routes exhibit similar pharmacokinetic profiles [46]. Recent data using preclinical *in vivo* models [47] indicate that omacetaxine shows good bioavailability via oral administration however Phase I data have not yet been reported for omacetaxine delivered via this route.

The success of imatinib and other TKIs has obviated the need for any further omacetaxine studies as a front-line therapy for CML; however, several [48-51] have suggested that combinations of omacetaxine with TKIs either in the front-line or salvage setting could provide synergistic activity, allow temporary or permanent TKI withdrawal, revitalized TKI activity in patients who have previously failed TKI due to mutations and/or to lead to an eventual cure for CML.

Omacetaxine has recently been resurrected as a potential treatment for refractory patients with the T315I mutation [52]. It is also being studied in a more recently recognized area of unmet need [53, 54]: patients who fail multiple TKIs regardless of mutational status. Preliminary data suggest that omacetaxine has utility in TKI resistant CML patients [43, 44] and the drug is currently being evaluated by the FDA at the time of writing this manuscript. Clinical studies have also shown activity of omacetaxine as a single agent or in combination with other therapies in AML [20-24, 46, 55-58], myelodysplastic syndrome (MDS) [59-61] and myeloproliferative neoplasms (MPN) [62]. Questions still remain as to what the correct dose or dosing combinations are most appropriate and whether maintenance and/or sequential therapy with omacetaxine and other therapies may have additional benefit in these cancers and in CML.

IN SUMMARY

Omacetaxine, compared to other therapeutic agents available today, provides a unique MOA in our fight against cancers. In this review we have described its MOA as a protein translation inhibitor and highlighted preliminary data about its possible effects against LICs and CSCs. Further studies that consolidate these early observations may improve treatment outcomes in CML patients and expand omacetaxine's role to other malignancies such as CLL, AML, MDS, MPN, multiple myeloma and potentially epithelial solid tumors. Finally, an effect against LICs and CSCs could open the door to utilize omacetaxine in combination, sequentially or maintenance treatment strategies with other therapeutic agents in a wide variety of cancers.

ACKNOWLEDGMENTS

Supported partially by a grant from the National Cancer Institute Grant CA16056 (MW). Both authors received research support from Chemgenex.

ABBREVIATION

4E-BP	=	4E-binding protein
AML	=	Acute myeloid leukemia
CLL	=	Chronic lymphocytic leukemia
CML	=	Chronic myeloid leukemia
CSCs	=	Cancer stem cells

eIF-4F	=	Elongation initiation factor 4F
FLICE	=	FAS-associated death-domain-like interleukin (IL)-1 β -converting enzyme inhibitory protein (c-FLIP _L)
LICs	=	Leukemia initiating cells
MNK1	=	Mitogen activated protein kinase interacting serine/threonine kinase 1
MOA	=	Mechanism of action
mTOR	=	Mammalian target of rapamycin
p90RSK	=	p90 ribosomal S6 kinase
PI3K	=	Phosphoinositide-3-kinase
TKI	=	Tyrosine kinase inhibitor
TNF	=	Tumor necrosis factor
TRAIL	=	TNF-related apoptosis-inducing ligand
Wnt	=	Wingless-type MMTV integration site family protein
XIAP	=	X-linked inhibitor of apoptosis

REFERENCES

- [1] Fresno M, Jimenez A, Vazquez D. Inhibition of translation in eukaryotic systems by harringtonine. *Eur J Biochem* 1977; 72(2): 323-30.
- [2] Huang MT. Harringtonine, an inhibitor of initiation of protein biosynthesis. *Mol Pharmacol* 1975; 11(5): 511-9.
- [3] Gurel G, Blaha G, Moore PB, Steitz TA. U2504 determines the species specificity of the A-site cleft antibiotics: the structures of tiamulin, homoharringtonine, and bruceantin bound to the ribosome. *J Mol Biol* 2009; 389(1): 146-56.
- [4] Hershey JWB, Miyamoto S. Translational control and cancer. In: Sonenberg N, Hershey JWB, Mathews MB, editors. *Translational Control of Gene Expression*. New York: Cold Spring Harbor Laboratory Press; 2000. pp. 637-54.
- [5] Silvera D, Formenti SC, Schneider RJ. Translational control in cancer. *Nat Rev* 2010; 10(4): 254-66.
- [6] Bordeleau ME, Robert F, Gerard B, *et al.* Therapeutic suppression of translation initiation modulates chemosensitivity in a mouse lymphoma model. *J Clin Invest* 2008; 118(7): 2651-60.
- [7] Robert F, Carrier M, Rawe S, Chen S, Lowe S, Pelletier J. Altering chemosensitivity by modulating translation elongation. *PLoS One* 2009; 4(5): e5428.
- [8] Chen R, Gandhi V, Plunkett W. A sequential blockade strategy for the design of combination therapies to overcome oncogene addiction in chronic myelogenous leukemia. *Cancer Res* 2006; 66(22): 10959-66.
- [9] Kuroda J, Kamitsuji Y, Kimura S, *et al.* Anti-myeloma effect of homoharringtonine with concomitant targeting of the myeloma-promoting molecules, Mcl-1, XIAP, and beta-catenin. *Int J Hematol* 2008; 87(5): 507-15.
- [10] Tang R, Faussat AM, Majdak P, *et al.* Semisynthetic homoharringtonine induces apoptosis via inhibition of protein synthesis and triggers rapid myeloid cell leukemia-1 down-regulation in myeloid leukemia cells. *Mol Cancer Ther* 2006; 5(3): 723-31.
- [11] Lin CJ, Cencic R, Mills JR, Robert F, Pelletier J. c-Myc and eIF4F are components of a feedforward loop that links transcription and translation. *Cancer Res* 2008; 68(13): 5326-34.
- [12] Lin CJ, Malina A, Pelletier J. c-Myc and eIF4F constitute a feedforward loop that regulates cell growth: implications for anticancer therapy. *Cancer Res* 2009; 69(19): 7491-4.
- [13] Branford S, Rudzki Z, Walsh S, *et al.* Detection of BCR-ABL mutations in patients with CML treated with imatinib is virtually always accompanied by clinical resistance, and mutations in the ATP phosphate-binding loop (P-loop) are associated with a poor prognosis. *Blood* 2003; 102(1): 276-83.
- [14] Parmar S, Smith J, Sassano A, *et al.* Differential regulation of the p70 S6 kinase pathway by interferon alpha (IFN α) and imatinib mesylate (STI571) in chronic myelogenous leukemia cells. *Blood* 2005; 106(7): 2436-43.
- [15] Ly C, Arechiga AF, Melo JV, Walsh CM, Ong ST. Bcr-Abl kinase modulates the translation regulators ribosomal protein S6 and 4E-

- BP1 in chronic myelogenous leukemia cells via the mammalian target of rapamycin. *Cancer Res* 2003; 63(18): 5716-22.
- [16] Zhang M, Fu W, Prabhu S, *et al.* Inhibition of polysome assembly enhances imatinib activity against chronic myelogenous leukemia and overcomes imatinib resistance. *Mol Cell Biol* 2008; 28(20): 6496-509.
- [17] Chen Y, Hu Y, Michaels S, Segal D, Brown D, Li S. Inhibitory effects of omacetaxine on leukemic stem cells and BCR-ABL-induced chronic myeloid leukemia and acute lymphoblastic leukemia in mice. *Leukemia* 2009; 23(8): 1446-54.
- [18] Kuroda J, Kimura S, Andreeff M, *et al.* ABT-737 is a useful component of combinatory chemotherapies for chronic myeloid leukaemias with diverse drug-resistance mechanisms. *Br J Haematol* 2008; 140(2): 181-90.
- [19] Xiang Z, Luo H, Payton JE, *et al.* Mcl1 haploinsufficiency protects mice from Myc-induced acute myeloid leukemia. *J Clin Invest* 2010; 120(6): 2109-18.
- [20] Kantarjian HM, Keating MJ, Walters RS, Koller CA, McCredie KB, Freireich EJ. Phase II study of low-dose continuous infusion homoharringtonine in refractory acute myelogenous leukemia. *Cancer* 1989; 63(5): 813-7.
- [21] Jin J, Jiang DZ, Mai WY, *et al.* Homoharringtonine in combination with cytarabine and aclarubicin resulted in high complete remission rate after the first induction therapy in patients with *de novo* acute myeloid leukemia. *Leukemia* 2006; 20(8): 1361-7.
- [22] Zhang WG, Wang FX, Chen YX, *et al.* Combination chemotherapy with low-dose cytarabine, homoharringtonine, and granulocyte colony-stimulating factor priming in patients with relapsed or refractory acute myeloid leukemia. *Am J Hematol* 2008; 83(3): 185-8.
- [23] Wang J, Lu S, Yang J, *et al.* A homoharringtonine-based induction regimen for the treatment of elderly patients with acute myeloid leukemia: a single center experience from China. *J Hematol Oncol* 2009; 2: 32.
- [24] Wu L, Li X, Su J, *et al.* Effect of low-dose cytarabine, homoharringtonine and granulocyte colony-stimulating factor priming regimen on patients with advanced myelodysplastic syndrome or acute myeloid leukemia transformed from myelodysplastic syndrome. *Leuk Lymphoma* 2009; 50(9): 1461-7.
- [25] Chen R, Guo L, Chen Y, Jiang Y, Wierda WG, Plunkett W. Homoharringtonine reduced Mcl-1 expression and induced apoptosis in chronic lymphocytic leukemia. *Blood* 2011; 117(1): 156-64.
- [26] Jin Y, Lu Z, Cao K, *et al.* The antitumor activity of homoharringtonine against human mast cells harboring the KIT D816V mutation. *Mol Cancer Ther* 2010; 9(1): 211-23.
- [27] Meng HT, Li L, Liu H, Wang Y, Li GC, Qian WB. Homoharringtonine acts synergistically with SG235-TRAIL, a conditionally replicating adenovirus, in human leukemia cell lines. *Acta Pharmacol Sin* 2009; 30(11): 1529-36.
- [28] Mawji IA, Simpson CD, Gronda M, *et al.* A chemical screen identifies anisomycin as an anokis sensitizer that functions by decreasing FLIP protein synthesis. *Cancer Res* 2007; 67(17): 8307-15.
- [29] Jorgensen HG, Holyoake TL. Characterization of cancer stem cells in chronic myeloid leukaemia. *Biochem Soc Trans* 2007; 35(Pt 5): 1347-51.
- [30] Rousselot P, Huguet F, Rea D, *et al.* Imatinib mesylate discontinuation in patients with chronic myelogenous leukemia in complete molecular remission for more than 2 years. *Blood* 2007; 109(1): 58-60.
- [31] Allan EK, Jorgensen HG, Michaels S, Holyoake TL, editors. Omacetaxine cytotoxic activity in chronic myeloid leukemia stem cells. *Haematologica* 2009; 1052 (abs).
- [32] Zhao C, Blum J, Chen A, *et al.* Loss of beta-catenin impairs the renewal of normal and CML stem cells *in vivo*. *Cancer Cell* 2007; 12(6): 528-41.
- [33] Hu Y, Chen Y, Douglas L, Li S. beta-Catenin is essential for survival of leukemic stem cells insensitive to kinase inhibition in mice with BCR-ABL-induced chronic myeloid leukemia. *Leukemia* 2009; 23(1): 109-16.
- [34] Broad Institute. [cited 2010]; Available from: <http://chembank.broadinstitute.org/chemistry/viewMolecule.htm?cbid=3176388>.
- [35] Klag T, Hartel N, Schenk T, Craig AR, Hochhaus A, Rosee PL. Downregulation of the common cytokine receptor subunit beta c by omacetaxine in CML: a potential molecular mechanism to overcome cytokine-mediated resistance against BCR-ABL-inhibitors. *Blood* 2009; 114(22): 3256 (Abs).
- [36] Gupta PB, Chaffer CL, Weinberg RA. Cancer stem cells: mirage or reality? *Nat Med* 2009; 15(9): 1010-2.
- [37] Gupta PB, Onder TT, Jiang G, *et al.* Identification of selective inhibitors of cancer stem cells by high-throughput screening. *Cell* 2009; 138(4): 645-59.
- [38] Kantarjian HM, Cortes J, La Rosee P, Hochhaus A. Optimizing therapy for patients with chronic myelogenous leukemia in chronic phase. *Cancer* 2010; 116(6): 1419-30.
- [39] O'Dwyer PJ, King SA, Hoth DF, Suffness M, Leyland-Jones B. Homoharringtonine--perspectives on an active new natural product. *J Clin Oncol* 1986; 4(10): 1563-8.
- [40] O'Brien S, Kantarjian H, Keating M, *et al.* Homoharringtonine therapy induces responses in patients with chronic myelogenous leukemia in late chronic phase. *Blood* 1995; 86(9): 3322-6.
- [41] O'Brien S, Talpaz M, Cortes J, *et al.* Simultaneous homoharringtonine and interferon-alpha in the treatment of patients with chronic-phase chronic myelogenous leukemia. *Cancer* 2002; 94(7): 2024-32.
- [42] Quintas-Cardama A, Kantarjian H, Cortes J. Homoharringtonine, omacetaxine mepesuccinate, and chronic myeloid leukemia circa 2009. *Cancer* 2009; 115(23): 5382-93.
- [43] Cortes-Franco J, Khoury HJ, Nicolini FE, *et al.* Safety and efficacy of subcutaneous-administered omacetaxine mepesuccinate in imatinib-resistant chronic myeloid leukemia (CML) patients who harbor the Bcr- Abl T315I mutation--results of an ongoing multicenter phase 2/3 study. *Blood* 2009; 114(22): 644 (Abs).
- [44] Cortes-Franco J, Raghunadharao D, Parikh P, *et al.* Safety and efficacy of subcutaneous-administered omacetaxine mepesuccinate in chronic myeloid leukemia (CML) patients who are resistant or intolerant to two or more tyrosine kinase inhibitors - results of a multicenter phase 2/3 Study. *Blood* 2009; 114(22): 861 (Abs).
- [45] Ni D, Ho DH, Vijjeswarapu M, Felix E, Rhea PR, Newman RA. Metabolism of homoharringtonine, a cytotoxic component of the evergreen plant *Cephalotaxus harringtonia*. *J Exp Ther Oncol* 2003; 3(1): 47-52.
- [46] Levy V, Zohar S, Bardin C, *et al.* A phase I dose-finding and pharmacokinetic study of subcutaneous semisynthetic homoharringtonine (ssHHT) in patients with advanced acute myeloid leukaemia. *Br J Cancer* 2006; 95(3): 253-9.
- [47] Brown D, Michaels S. Design and evaluation of oral delivery dosage forms of homoharringtonine. *AACR Annual Meeting Abstracts* 2007; Abstract 4730.
- [48] Tipping AJ, Mahon FX, Zafirides G, Lagarde V, Goldman JM, Melo JV. Drug responses of imatinib mesylate-resistant cells: synergism of imatinib with other chemotherapeutic drugs. *Leukemia* 2002; 16(12): 2349-57.
- [49] Marin D, Kaeda JS, Andreasson C, *et al.* Phase I/II trial of adding semisynthetic homoharringtonine in chronic myeloid leukemia patients who have achieved partial or complete cytogenetic response on imatinib. *Cancer* 2005; 103(9): 1850-5.
- [50] Bruey JM, Kantarjian HM, Ma W, *et al.* A Common but Overlooked Mechanism of BCR-ABL1 Kinase Inhibitor Resistance in Chronic Myeloid Leukemia. *Blood* 2009; 114(22): 2179.
- [51] Ayoubi M, Kantarjian HM, Wierda W, *et al.* A phase 2 study of the combination of omacetaxine and imatinib in the treatment of patients with chronic myeloid leukemia (CML) in advanced stages or after failure to imatinib. *Blood* 2009; 114(22): 2193 (Abs).
- [52] Nicolini FE, Chomel JC, Roy L, *et al.* The durable clearance of the T315I BCR-ABL mutated clone in chronic phase chronic myelogenous leukemia patients on omacetaxine allows tyrosine kinase inhibitor rechallenge. *Clin Lymphoma Myeloma Leuk* 2010; 10(5): 394-9.
- [53] Tam CS, Kantarjian H, Garcia-Manero G, *et al.* Failure to achieve a major cytogenetic response by 12 months defines inadequate response in patients receiving nilotinib or dasatinib as second or subsequent line therapy for chronic myeloid leukemia. *Blood* 2008; 112(3): 516-8.
- [54] Garg RJ, Kantarjian H, O'Brien S, *et al.* The use of nilotinib or dasatinib after failure to 2 prior tyrosine kinase inhibitors: long-term follow-up. *Blood* 2009; 114(20): 4361-8.
- [55] Okano T, Ohnuma T, Holland JF, Koeffler HP, Jui H. Effects of harringtonine in combination with acivicin, adriamycin, L-asparaginase, cytosine arabinoside, dexamethasone, fluorouracil or methotrexate on human acute myelogenous leukemia cell line KG-1. *Invest New Drugs* 1983; 1(2): 145-50.

- [56] Warrell RP, Jr., Coonley CJ, Gee TS. Homoharringtonine: an effective new drug for remission induction in refractory nonlymphoblastic leukemia. *J Clin Oncol* 1985; 3(5): 617-21.
- [57] Feldman E, Arlin Z, Ahmed T, *et al.* Homoharringtonine is safe and effective for patients with acute myelogenous leukemia. *Leukemia* 1992; 6(11): 1185-8.
- [58] Feldman E, Arlin Z, Ahmed T, *et al.* Homoharringtonine in combination with cytarabine for patients with acute myelogenous leukemia. *Leukemia* 1992; 6(11): 1189-91.
- [59] Feldman EJ, Seiter KP, Ahmed T, Baskind P, Arlin ZA. Homoharringtonine in patients with myelodysplastic syndrome (MDS) and MDS evolving to acute myeloid leukemia. *Leukemia* 1996; 10(1): 40-2.
- [60] Borthakur G, Kantarjian H, Estey E, Verstovsek S, Garcia-Manero G, Cortes J. Study of intra-venous homoharringtonine (HHT) in the treatment of myelodysplastic syndrome (MDS). *Blood* 2005; 106(11): 4903 (Abs).
- [61] Xu WL, Jin J, Qian WB. Homoharringtonine in combination with cytarabine and aclarubicin as induction therapy improves remission and survival of patients with higher risk myelodysplastic syndromes. *Chin Med J (Engl)* 2010; 123(1): 108-10.
- [62] Lu LH, Lin SP, Liang YY, Song TY, Li LY. Harringtonine in treatment of polycythemia vera. *Chin Med J (Engl)* 1983; 96(7): 533-5.

Received: January 5, 2011

Accepted: February 1, 2011